Loading...

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

3:39

Pharmaceutical Executive Daily: FDA Approves Utebzi...

Pharmaceutical Executive ·

2026/06/18

In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections, and FDA expands the indication for Merck's Capvaxive to include children and adolescents aged 2 through 17 with chronic medical conditions at increased risk for pneumococcal disease.

en-us

3:34

Pharmaceutical Executive Daily: Meaningfully...

Pharmaceutical Executive ·

2026/06/17

In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundup covers Merck's $510 million collaboration with Protillion Biosciences and Jazz Pharmaceuticals' multi-program antibody discovery deal with AbCellera, and Jack McFeely argues that behavioral and engagement insights are the missing ingredient in patient support programs that struggle to sustain long-term persistence.

en-us

4:00

Pharmaceutical Executive Daily: FDA has Approved...

Pharmaceutical Executive ·

2026/06/16

In today's Pharmaceutical Executive Daily, Elicio Therapeutics shares tumble after its Phase II Amplifgy-7P trial of KRAS-targeting immunotherapy ELI-002 7P misses its primary endpoint in adjuvant pancreatic cancer, FDA approves Skinvive by Juvéderm as the first and only hyaluronic acid injectable indicated to reduce neck lines, and Pharmaceutical Executive speaks with Dr. Edward Littler and Dave Watson, the newly paired executive chairman and CEO of Persica Pharmaceuticals, on how they are driving

en-us

3:19

Pharmaceutical Executive Daily: FDA Approves Two...

Pharmaceutical Executive ·

2026/06/15

In today's Pharmaceutical Executive Daily, Boehringer Ingelheim's Brian Hilberdink argues that obesity innovation must evolve beyond the scale, a pharma regulatory roundup covers two significant FDA approvals, and Pharmaceutical Executive speaks with Raj Indupuri, CEO of eClinical Solutions, on making the ROI case for smarter clinical trials in an era of exploding trial data complexity.

en-us

3:23

Pharmaceutical Executive Daily: Kardigan Sets Terms...

Pharmaceutical Executive ·

2026/06/12

In today's Pharmaceutical Executive Daily, Kardigan sets terms for a $350 million IPO that would value the cardiovascular biotech at approximately $1.3 billion, Pharmaceutical Executive speaks with Rick Winningham on building the next generation of leaders behind the pipeline, and Jazz Pharmaceuticals reports that the Phase III Lagoon trial of Zepzelca failed to meet its primary endpoint of overall survival in second-line small cell lung cancer.

en-us

3:10

Pharmaceutical Executive Daily: China's Latest Policy...

Pharmaceutical Executive ·

2026/06/11

In today's Pharmaceutical Executive Daily, Bruce Liu examines China's latest policy guidance establishing premium pricing and priority reimbursement access for truly innovative drugs, Parabilis Medicines surges more than 45 percent on its first day of trading on Nasdaq, and Pharmaceutical Executive speaks with Eli Lilly's Sarah O'Keeffe, Group Vice President of Product Research and Development, on how the company's $4.5 billion Medicine Foundry is designed to transform the discovery-to-production

en-us

2:58

Pharmaceutical Executive Daily: Parabilis Medicines...

Pharmaceutical Executive ·

2026/06/10

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech AlzeCure Pharma enters a collaboration and out-licensing agreement with Eli Lilly for its Alzheimer's candidate, and FDA approves an every-eight-week maintenance dosing regimen for Eli Lilly's Ebglyss.

en-us

7:51

The Ron Lanton Report: From Innovation to Infrastructure

Pharmaceutical Executive ·

2026/06/10

In this episode, Ron Lanton draws on insights from the JP Morgan Healthcare Conference to explain how healthcare investment is shifting from backing novel ideas to funding organizations that can scale, survive regulatory and reimbursement pressure, and embed technology into the operational infrastructure of care delivery.

en-us

3:31

Pharmaceutical Executive Daily: GSK Acquires Nuvalent...

Pharmaceutical Executive ·

2026/06/09

In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh capital, GSK announces a $10.6 billion agreement to acquire Nuvalent in its largest deal in over a decade, , and Pharmaceutical Executive speaks with David Coman, CEO of BGBx, on why the firm's rebranding from BGB reflects a broader shift in how biopharma commercialization now demands integrated consulting, communications, and scientific frameworks.

en-us

4:23

Pharmaceutical Executive Daily: Roche and Nurix...

Pharmaceutical Executive ·

2026/06/08

In today's Pharmaceutical Executive Daily, Roche and Nurix Therapeutics announce a global collaboration, a pharma M&A roundup covers three deals announced today, and Pharmaceutical Executive contributors examine how an emerging wave of biologics is signaling a new treatment era in alopecia areata beyond the established JAK inhibitor class.

en-us

2:58

Pharmaceutical Executive Daily: Supreme Court...

Pharmaceutical Executive ·

2026/06/05

In today's Pharmaceutical Executive Daily, the Supreme Court unanimously rules in favor of Hikma Pharmaceuticals in its patent dispute with Amarin over Vascepa, Pfizer licenses Chai Discovery's generative AI platform, and C.K. Wang argues that high-quality real-world data represents the most promising path forward for closing persistent gaps in ovarian cancer care.

en-us

3:03

Pharmaceutical Executive Daily: Alnylam...

Pharmaceutical Executive ·

2026/06/04

In today's Pharmaceutical Executive Daily, Eli Lilly escalates its 340B enforcement standoff by notifying covered entities of a five-business-day window to submit required claims data or lose access to 340B pricing, Alnylam Pharmaceuticals and Inceptive Nucleics announce a three-year strategic AI collaboration worth up to $2 billion, and Anne Marie Robertson of Eversana speaks on the trends shaping the future of oncology commercialization following ASCO 2026.

en-us

35:28

Navigating PBM Pitfalls: Protecting Revenue in a...

Pharmaceutical Executive ·

2026/06/04

In this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to offer a candid, expert-driven look at the pharmacy benefit manager (PBM) landscape, including the operational complexities confronting biopharma manufacturers and what these companies must understand to protect their revenue and expand patient access. Mendelsohn cuts through the spin to examine where PBM reform efforts are progressing and falling short, how payer

en-us

3:14

Pharmaceutical Executive Daily: New FDA Draft...

Pharmaceutical Executive ·

2026/06/03

In today's Pharmaceutical Executive Daily, Cam Olig of Prescryptive Health touches on the results of a new market access survey, Eli Lilly and Ascidian Therapeutics announce a global research collaboration worth up to $1.9 billion to develop RNA exon editors for inherited kidney diseases, and the FDA issues new draft guidance to reduce the submission burden for gene therapy developers.

en-us

3:23

Pharmaceutical Executive Daily: FDA Sends Complete...

Pharmaceutical Executive ·

2026/06/02

In today's Pharmaceutical Executive Daily, FDA has accepted a new drug application for giredestrant under priority review, FDA also issues a complete response letter for Cingulate's CTx-1301, and Dan Troy, former FDA Chief Counsel, explains the roadblocks and hurdles facing the FDA's efforts to bring stricter oversight to direct-to-consumer prescription drug advertising.

en-us

3:40

Pharmaceutical Executive Daily: FDA Approves Xocova

Pharmaceutical Executive ·

2026/06/01

In today's Pharmaceutical Executive Daily, the FDA approves Shionogi's Xocova, a pharma M&A roundup covers Servier's acquisition of Edgewise Therapeutics' muscular dystrophy, Eli Lilly's licensing of Hanmi's long-acting GLP-2 therapy, and the merger of Rallybio and Avenzo Therapeutics, finally Sean Werner examines why breakthrough cell and gene therapies continue to fail at the regulatory finish line.

en-us

2:57

Pharmaceutical Executive Daily: WHO Identifies...

Pharmaceutical Executive ·

2026/05/29

In today’s Pharmaceutical Executive Daily, Harpreet Singh discusses the evolving regulatory landscape for biopharma, the World Health Organization identifies three priority treatment candidates for the Bundibugyo strain of Ebola virus disease, and this week’s pharma roundup highlights new findings on Mounjaro and long COVID-related immune system changes.

en-us

2:43

Pharmaceutical Executive Daily: CVS Health to Offer...

Pharmaceutical Executive ·

2026/05/28

In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s Zepbound while adding the company’s newly approved obesity pill Foundayo, and experts discuss how treatment expectations are evolving in lupus care.

en-us

2:57

Pharmaceutical Executive Daily: FDA Approves Hepcludex

Pharmaceutical Executive ·

2026/05/26

In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA approves Hepcludex as the first treatment for chronic hepatitis delta virus infection in the United States, and biotech finance leaders reflect on the lessons learned from navigating two decades of volatile markets.

en-us

2:26

Pharmaceutical Executive Daily: FDA Approves Datroway

Pharmaceutical Executive ·

2026/05/22

en-us

461 results

Similar Podcasts

Planetterrian Daily

Patrick · Nerra Network

New Books in Science, Technology, and Society

New Books Network

Scifi Friday

Radio Memories Network

The Bio Report

Levine Media Group

Waterlines: How Water Shapes Our World

jaywen